Zacks analyst blog spotlights Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker
For immediate release
Chicago, IL – June 15, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Microsoft Corp. MSFT, Amgen Inc. AMGN, Honeywell International Inc. HON, Booking Holdings Inc. BKNG and Stryker Corp. SYK.
Here are the highlights from Tuesday’s analyst blog:
Top research reports for Microsoft, Amgen and Honeywell
Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Microsoft Corp., Amgen Inc. and Honeywell International Inc. These research reports have been handpicked from the nearly 70 reports published by our analyst team today.
Microsoft stocks have held up better than the broader tech sector in the continued market decline (down -19.6% year-to-date vs. -24.2% for the Zacks Tech sector), reflecting the well-positioned anchored the company in space. But the stock nonetheless lagged the broader market as investors reassessed the risks associated with a faster-growing software player in a rising interest rate environment.
Nonetheless, Microsoft’s performance is benefiting from the strength of its Azure cloud platform amid accelerating global digital transformation. Teams user growth is benefiting from continued remote working and the widespread adoption of hybrid/flexible work models.
The recovery in the advertising and employment markets boosted LinkedIn and search revenue. Solid adoption of new Xbox consoles is contributing to the performance of the gaming segment. The company is witnessing a growth in the user base of its various applications, including the Microsoft 365 suite, Dynamics and Power Platform. Microsoft expects Surface revenue to grow in the mid-teens, driven by strong demand for high-end devices.
Amgen Shares have outperformed the Zacks Medical – Biomedical & Genetics sector over the past year (+2.1% vs -45.5%) thanks to a strong portfolio of early and late stage assets. Multiple Phase III readouts are expected in 2022. Lumakras, a first-in-class lung cancer treatment, is off to a strong start as its label expansion studies progress rapidly. Amgen has a strong biosimilar pipeline with potential new products that should drive long-term growth.
However, pricing and competitive pressure impact many Amgen products and franchises. Several of the drugs marketed by Amgen are facing price headwinds. The IRS tax dispute is an overhang on Amgen shares. Additionally, growing competition for its legacy products is hurting sales.
Honeywell the shares performed better than the peer group as well as the broader market during the ongoing market weakness, reflecting the company’s operational excellence and favorable outlook for its key end markets.
The Zacks analyst believes the company will benefit from strength in productivity solutions and services, advanced sensing technologies and gas detection businesses. For 2022, the company expects organic revenue to grow 4-7% year-over-year. It is likely to benefit from acquisitions made over time.
Additionally, the company’s ability to generate strong cash flow adds to its strength. It generously rewards shareholders through dividends and share buybacks.
Other noteworthy reports we’re featuring today include Booking Holdings Inc. and Stryker Corp.
Why haven’t you watched Zacks best action?
Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared+40.3%, +48.2%, +67.6%, +94.4%, and+95.3%. Today, you can access their live selections at no cost or obligation.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor more information on the performance figures displayed in this press release.
Zacks’ Top Picks for Leveraging Electric Vehicles
A lot of money has already been made in the electric vehicle (EV) industry. But the electric vehicle revolution has not yet reached full steam. There’s a lot of money to be made as the next push for future technologies gathers pace. Zacks special report reveals 5 top investors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.